Tonacea Launches Self-Discipline Convention Endorsed by Over 100 CGT Companies

Jul 28,2026

A 6-year-old girl's death in 2025 after receiving a brain-targeted gene-editing therapy in Shanghai has dominated headlines in recent days.


The full story remained hidden for a year, until a joint investigation by Science and Retraction Watch was published on July 23, bringing it to the attention of the industry and the public.


The investigation revealed that the girl, identified by the pseudonym "Mei," suffered from a rare CHD3 gene mutation syndrome. Her parents paid $860,000 to fund the brain-targeted gene-editing research. However, seven days after receiving an AAV vector infusion, Mei died from thrombotic microangiopathy. The hospital's ethics committee determined that the death was "definitely related" to the experimental treatment.


According to the Science investigation, the research team failed to adequately inform the family of the risk of death. After the final primate toxicology report revealed liver and kidney damage, the relevant data were not submitted to the ethics committee for re-review. In addition, approximately $130,000 in research funds were transferred to a researcher's personal account.


In February 2026, the research team published a preclinical paper in Nature. The final paper removed all references to the girl's family and their financial support, and failed to disclose the girl's death or the liver and kidney damage observed in the primate safety studies.


Drug innovation requires courage, and medical progress depends on bold exploration. However, new drug development must always uphold a profound reverence for life. Every step forward must be subject to ethical calibration, regulatory constraints, and transparent oversight.


This incident has exposed systemic problems—including delayed ethics committee reviews, inadequate informed consent, and failure to publicly disclose adverse events—sounding a wake-up call for the entire industry.


Following widespread media coverage, intense discussions erupted within the Tonacea CGT President WeChat group. Founders of multiple cell and gene therapy companies agreed that the issues exposed by the research team represented a serious departure from the fundamental ethics and scientific principles of drug development.


Many expressed that while cutting-edge biomedical exploration requires a pioneering spirit, all scientific research must be conducted with the utmost reverence for life and a firm commitment to research integrity. Complete ethical oversight, transparent trial management, and full risk disclosure are essential to safeguarding the rights of trial participants and strengthening the public health defense line.


Against this backdrop, Tonacea Cell and Gene Therapy Club swiftly launched the Industry Self-Discipline Initiative on Standardizing Research Conduct and Upholding Scientific Ethics. The initiative was co-launched by Zengjiang Cheng(Vice President of the China Food and Drug Safety Promotion Association, Founder and Chairman of Tonacea),Yu Zhang(Chairman of Tonacea Cell and Gene Therapy Club, Director and Co-CEO of VCANBIO),Grace Zhou(Vice Chairman of the Tonacea Cell and Gene Therapy Club, Founder, Chairwoman and CEO of ImmVira). It quickly garnered broad support from China's CGT companies. As of 11:00 AM on July 29, a total of 105 founders, CEOs and senior executives from the CGT sector have endorsed the initiative—a powerful demonstration of the industry's collective commitment to upholding research ethics and self-discipline.


China's new drug R&D is at a critical stage of transition—from "following" to "running alongside" and even "leading" globally. The CGT field, as one of the most cutting-edge areas in biomedicine, carries the hopes of countless patients and the expectation that China's biopharmaceutical industry will make a leapfrog advance. Yet it is precisely at such a critical juncture that a clear mind and firm bottom lines are most needed.


Technological innovation can be bold, but it must always operate within the framework of ethics and regulations—this is a fundamental consensus of modern medical civilization and a prerequisite for Chinese innovative drugs to gain global recognition. The long-term prosperity of an industry is never built on a few top-journal papers or "first-ever" achievements, but on society's enduring trust in its rigor and sense of responsibility. Once trust is broken, the cost of rebuilding it will be immeasurable.


The launch of this Self-Discipline Convention is laying the groundwork for the future of China's CGT industry—making compliance a habit, integrity a part of its DNA, and ensuring that Chinese innovative drugs not only move fast but also move steadily and far. As the initiative states: "Let this incident serve as a mirror for us: keep our promises in mind, shoulder our responsibilities."

 

 

The full text of the convention is as follows:

 

Initiator:


程增江:中国食药安全促进会副会长、同写意创始人/董事长
Zengjiang Cheng:Vice President of the China Food and Drug Safety Promotion Association, Founder and Chairman of Tonacea

 

张 宇:同写意CGT俱乐部理事长、中源协和董事,联席总裁
Yu Zhang:Chairman of Tonacea Cell and Gene Therapy Club, Director and Co-CEO of VCANBIO

 

周国瑛:同写意CGT俱乐部副理事长、亦诺微医药董事长
Grace Zhou:Vice Chairman of the Tonacea Cell and Gene Therapy Club, Founder, Chairwoman and CEO of ImmVira

 

 

Co-signatories (listed in alphabetical order by Pinyin surname):

 

鲍 健:熠旋生物联合创始人、CEO
Jian Bao : Co-founder and CEO of Yixuan Biotech

 

才 源:盛大网络代谢健康实验室AAV项目负责人
Yuan Cai : Executive Director of AAV Platform, Peraxis Lab, Shanda Group

 

蔡 欣:星奥拓维总裁
Xin Cai : President of Otovia Therapeutics

 

陈 功:神曦生物创始人、董事长
Gong Chen : Founder and Chairman of NeuExcell Therapeutics

 

陈槾羲:百吉生物联席董事长
Michelle Chen: Co-Chairman of Biosyngen

 

陈 强:科金生物首席技术官兼香港子公司首席执行官
Qiang Chen : CTO & CEO of HongKong ,DanausGT Biotechnology Limited

 

陈 旭:依科赛生物创始人、董事长
Xu Chen : Founder and Chairman of ExCell Bio

 

崔文浩:佑嘉生物创始人、董事长
Wenhao Cui : Founder and Chairman of Youjia Bio

 

戴 勇:源奕生物创始人、CEO
Yong Dai:Founder & CEO of Codexa Therapeutics

 

戴卫国:门罗生物联合创始人、CEO
Weiguo Dai: Co-Founder & CEO, Menlo Biotech

 

董 飚:至善唯新创始人、董事长
Biao Dong: Founder, Chairman of Real &Best Biotech

 

范 靖:霍德生物创始人、CEO
Jing Fan : Founder and CEO of Hopstem Biotechnology LLC

 

范晓虎:湾岛细胞创始人
Frank Fan: Founder CEO of Wondercel Therapeutics

 

傅雪梅:健达九州CEO
Xuemei Fu : CEO of GenAns Biotechnology Co., Ltd

 

高 璐:佑音医药CEO
Lu Gao : CEO of Euhearing Therapeutics

 

高 青:华赛伯曼联合创始人、董事长
Qing Gao: Co-Founder and Chairman, HUASAIBIO

 

高晓飞:西湖生物创始人、董事长
Xiaofei Gao : Founder and Chairman of Westlake Therapeutics

 

谷为岳:北京卡替医疗创始人、董事长
Weiyue Gu: Founder & Chairman, Chineo  Medical Technology Co.,Ltd.

 

郭  莹:夏同生物创始人、CEO
Ying Guo: Founder & CEO, ExoNeuglia Biotechnology Co.,Ltd.

 

郭志刚:南京奇迹生物董事长兼首席科学官
Daniel Guo: Chairman & CSO of Nanjing Miracle Biotechnology Co., Ltd

 

何春艳:新芽基因创始人、CEO
Chunyan He: Founder and CEO, GenAssist Ltd

 

何映珂:生葆生物CEO
Yingke He : CEO of Shengbao Biotech

 

胡荣宽:星锐医药创始人、CEO
Frank Hu: Founder & CEO, Starna Therapeutics

 

胡 洋:微光基因创始人、CEO
Young Hu: Founder & CEO, Lumiere Therapeutics

 

黄文林:广州达博生物创始人、董事长
Wenlin Huang: Founder and Chairman, Guangzhou Doublle Bioproducts INC.

 

黄 飞:恒润达生生物联合创始人、CEO
Fei Huang: Co-founder & CEO of HRAIN Biotechnology Co.,Ltd.

 

姜儒鸿:ASC Therapeutics (ASCT) 创始人、董事长、CEO
Ruhong Jiang : Founder, Chairman and CEO of ASC Therapeutics (ASCT)

 

金华君:君赛生物创始人、董事长兼CEO
Huajun Jin : Founder,Chairman and CEO of Juncell Therapeutics

 

周 露:神拓生物创始人、CEO
Lu Zhou : Founder & CEO of Santo Therapeutics

 

李华鹏:派真生物创始人、董事长、首席科学家
Huapeng Li : Founder, Chairman and Chief Scientist of Paizhen Biotech

 

李 骏:科锐克医药创始人、总经理
Jun Li : Founder and CEO of CorreGe Therapeutics

 

李 翔:士泽生物创始人、CEO
Xiang Li : Founder and CEO of Xellsmart

 

李新燕:芳拓生物CEO兼CMO
Xinyan Li : CEO and CMO of Frontera Therapeutics

 

李园园:三启生物总经理
Yuanyuan Li : General Manager of Sanqi Biotech

 

李宗海:科济药业创始人、董事会主席、首席执行官、首席科学官
Zonghai Li : Founder, Chairman, CEO and CSO, CARsgen Therapeutics

 

李诣书:博雅生命创始人、CEO
Lisa Li: Founder and CEO of Boyalife Inc

 

栗红建:普瑞金生物董事长
Hongjian Li : Chairman of Pregene

 

梁峻彬:瑞风生物创始人、CEO
Junbin Liang: Founder & CEO, Reforgene Medicine

 

林 卿:凌意生物创始人、董事长兼CEO
Andrew Lin: Founder,Chairman and CEO of Lingyi Biotech

 

林 欣:华夏英泰创始人
Xin Lin: Founder,BriSTAR Immunotech Ltd.

 

林华兵:舒桐医疗创始人、总经理
Huabing Lin: Founder&CEO of GeneRulor

 

刘滨磊:滨会生物创始人、董事长、总经理
Binlei Liu : Founder, Chairman and General Manager of BinHui Biotech


刘凌峰:羿尊生物创始人、CEO&CSO
Steven Liu: Founder, CEO & CSO of ST Phi Therapeutics

 

刘胜江:Avirmax 创始人、董事长、CEO兼CSO
Shengjiang Liu : Founder, Chairman, CEO & CSO of Avirmax

 

刘 韬:默赛尔生物董事长
Tao Liu : Chairman,Morecell biomedical technology development co., Ltd.

 

刘雅容:沙砾生物创始人、董事长
Yarong Liu: Founder and Chairman, Grit Biotechnology

 

刘 杨:赛赋医药创始人、董事长
Yang Liu : Founder and Chairman of Saifu  laboratories

 

刘 密: 苏州尔生生物医药创始人、CEO, 
Mi Liu : Founder & CEO, Suzhou Ersheng Biopharmaceutical

 

陆金华:星尘生物联合创始人、CSO
Jinhua Lu : cofounder, CSO, TriArm Therapeutics Co., Ltd.

 

孟锐锋:欣协生物创始人、CEO
James Meng: Founder & CEO,Shanghai Xinbio

 

廖 成:瑞宏迪医药创始人、CEO
Cheng Liao:Founder and CEO of Shanghai Regenelead Therapies Co., Ltd.

 

潘国宇:上海微知卓生物董事长
Guoyu Pan: Founder and Chairman of Shanghai Hexaell Biotech

 

潘讴东,和元生物创始人、董事长
Oudong Pan: Founder & Chairman, OBiO TECH

 

彭 林:神济昌华联合创始人、首席执行官
Lin Peng : Co-founder and CEO of Shenji Changhua

 

彭晓明:来恩生物CEO
Xiaoming Peng : CEO of Lion TCR

 

彭松明:新景智源生物创始人、CEO
Songming Peng : Founder and CEO of neowise biotechnology

 

沈于阗:赛隽生物联合创始人、CEO
Yutian Shen : Co-founder and CEO of Saijun Biotech

 

苏彦景:美纳智信生物董事长
Yanjing Su : Chairman of MaRiNA Biotherapeutics Inc

 

孙敏敏:易慕峰生物创始人、董事长、CEO
Minmin Sun : Founder, Chairman and CEO of Immunofoco

 

宋相容:威斯津生物科学创始人兼CEO
Xiangrong Song: Scientific Co-founder and CEO of WestGene Biopharma Co.,Ltd

 

尚小云:茂行生物创始人、CEO
Xiaoyun Shang: Founder and CEO of T-MAXIMUM Pharmaceutical Inc.

 

谭青乔:鼎新基因联合创始人、首席技术官
Qingqiao Tan: Co-fouder &CSO of Refreshgene Therapeutics

 

钱  程:重庆精准生物创始人,董事长兼CEO
Cheng Qian: Founder,Chairmen and CEO of Chongqing Precision Biotech

 

王立军:行诚生物董事长兼CEO
Lijun Wang : Chairman and CEO of CoJourney

 

王立群:星奕昂生物创始人、董事长
Richard Wang : Founder and Chairman, Neukio Biotherapeutics

 

王少鹏:睿愈生物COO
Shaopeng Wang: COO, Modit Therapeutics

 

王文石:复星凯瑞技术运营高级副总裁
Wenshi Wang : Senior Vice President of Technical Operations of Fosun Karyo

 

王 维:中因科技CEO
Wei Wang:CEO of Chigenovo

 

王文博:立凌生物创始人、CEO
Wenbo Wang: Founder & CEO of LeaLing Biopharma

 

魏 君:睿健医药创始人、CEO
Jun Wei: Co-Founder and CEO , iRegene Therapeutics

 

吴昊泉:康霖生物创始人、CEO
Haoquan Wu : Founder and CEO of Kanglin Biotech


吴岚林:跃赛生物CEO
Lanlin Wu : CEO of UniXell Biotechnology

 

吴宇轩:尧唐生物创始人、CEO
Yuxuan Wu : Founder & CEO, YolTech Therapeutics

 

吴振华:杭州嘉因生物创始人/CEO
Zhenhua Wu : Founder and CEO of Hangzhou Jiayin Biotech

 

肖 啸:信念医药董事长、CSO
Xiao Xiao: Chairman and CSO of Belief BioMed

 

项健行:立博泰克CEO
Jianxing Xiang: CEO of Libiotek

 

徐元元:克睿基因创始人、CEO
Yuanyuan Xu: Founder and CEO of Cure Genetics

 

徐天宏:贝斯生物创始人、CEO 
Tianhong Xu: Founder and CEO of Base Therapeutics

 

鄢和新:赛立维生物创始人、董事长兼CEO
Hexin Yan : Founder,Chairmen and CEO of Celliver Biotech

 

杨焕凤:原启生物联合创始人、董事长、CEO
Helen Yang : Co-founder,CEO and Chairman, Oricell.

 

杨佳银:三启生物联合创始人、CTO
Jiayin Yang: co-founder & CTO of Cell Inspire Biotechnology

 

杨 林:博生吉医药创始人、董事长
Lin Yang: Founder and Chairman, PersonGen BioTherapeutics

 

杨美家:杭州引界生物创始人、董事长兼CSO
Meijia Yang : Founder, Chairman and CSO of Hangzhou Navigen Biopharmaceutical Co., Ltd.

 

杨一杰:汇芯生物联合创始人、CEO
Jet Yang : Co-founder and CEO of EXODUS Bio

 

雍 军:极客基因创始人、CEO
Jun Yong : Founder & CEO of GeekGene Technology


俞 磊:上海优卡迪生物医药科技创始人,董事长兼CEO
Lei Yu : Founder,Chairman and CEO of Unicar-Therapy

 

袁 明:深圳华药康明董事长
Ming Yuan : Chairman of Shenzhen Hua Yao Kang Ming Biopharmaceutical Co., Ltd.

 

曾 钢:偲礼生物创始人、CEO
Gang Zeng: Founder and CEO of Sili Biotech

 

张 杰:星尘生物联合创始人、总裁
Jie Zhang: Co-founder and President of Xingchen Biotech

 

张金华:驯鹿生物创始人、董事长兼CEO
Jinhua Zhang : Founder, Chairman and CEO of IASO BIO

 

张 婷:吉美瑞生CEO
Ting Zhang :CEO of Ji Mei Rui Sheng

 

张 勇:大华凯特生物董事、副总裁
Yong Zhang : Director and Vice President of Dahua Kaite Biotech

 

张 宇:中源协和董事、联席总裁
Yu Zhang: Director and Co-CEO of VCANBIO

 

赵丕明:道济基因创始人、CEO
Piming Zhao : Founder and CEO of Daoji Gene

 

赵晓剑:百因诺生物董事长兼CEO
Xiaojian Zhao : Chairman and CEO of Bioinno Bio

 

赵小平:天泽云泰联合创始人、董事长兼CEO
Xiaoping Zhao :  Co-founder,Chairman and CEO of Vitalgen

 

赵阳兵:优替济生生物联合创始人、总裁兼首席科学家
Yangbing Zhao: Co-founder, President and Chief Scientist of UTC Therapeutics Inc.

 

赵 哲:睿芙细胞创始人、CEO
Zhe Zhao:Founder and CEO of Rifiorire Bio

 

郑维义:苏州诺景生命科技创始人、CEO
Weiyi Zheng : Founder & CEO of Suzhou Nuojing Life Technology Co., Ltd

 

钟桂生:玮美基因创始人
Guisheng Zhong  : Founder of Weimei Gene

 

钟晓松:卡瑞济药业,创始人兼董事长
Michel Zhong: Founder and Chairman of Carriage Therapeutics

 

周国瑛:亦诺微医药创始人、董事长兼CEO
Grace Zhou : Founder, Chairman and CEO , ImmVira

 

周静敏:鲸奇生物联合创始人、CEO
Jingmin Zhou : Co-Founder & CEO of Genemagic Biosciences

 

朱 朝:纽伦捷生物董事长、CEO
Zhao Zhu: Chairman and CEO, Neuregen Therapeutics

 

章康健:元宋生物董事,联合创始人,总经理
Kangjian Zhang: Co-Founder and CEO, Yuansong Bio